Woodline Partners LP Purchases New Position in Atyr PHARMA INC (NASDAQ:ATYR)

Woodline Partners LP acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,683,000 shares of the company's stock, valued at approximately $6,092,000. Woodline Partners LP owned about 2.01% of Atyr PHARMA as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Group One Trading LLC purchased a new position in shares of Atyr PHARMA during the fourth quarter valued at $26,000. Alterna Wealth Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $37,000. Raymond James Financial Inc. purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $39,000. Finally, XTX Topco Ltd purchased a new stake in Atyr PHARMA in the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 61.72% of the company's stock.

Wall Street Analyst Weigh In

ATYR has been the subject of a number of research analyst reports. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Leerink Partners initiated coverage on shares of Atyr PHARMA in a research report on Tuesday, February 18th. They issued an "outperform" rating and a $16.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Monday, May 19th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Stock Up 2.5%

Shares of ATYR traded up $0.11 during mid-day trading on Thursday, hitting $4.31. 1,037,753 shares of the company's stock were exchanged, compared to its average volume of 943,222. The firm has a fifty day moving average of $3.25 and a two-hundred day moving average of $3.43. Atyr PHARMA INC has a twelve month low of $1.42 and a twelve month high of $4.90. The stock has a market cap of $383.16 million, a price-to-earnings ratio of -4.57 and a beta of 0.79. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, sell-side analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current year.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.